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tis in the past. His family was free of coronary artery disease and the pa-
tient was not taking any medications on a regular basis. He admitted
that he had used marijuana for 6 years, kubar (a substance preparation
produced by pulverizing leaves and seeds of female C. sativa andmixing
them with pulverized marijuana) for 4 years, and bonzai (a type ofKeywords:
Cannabis
Acute coronary syndrome
Renal failurea 1/6 systolic murmur in aortic focus. Respiratory and other system ex-Introduction
The chemical substance cannabis, which is produced from the leaves
of the plant Cannabis sativa, is commonly used by youth in Europe and
in our country.1 Although heroin, ecstasy, and cocaine have been
known to be associated with adverse health effects, there is a common
belief in society that cannabis is a relatively benign substance, just
like alcohol and tobacco. In addition to its pleasure-inducing actions,
C. sativa has also some side effects in various organ systems, particularly
the cardiovascular system, and may sometimes threaten life.2 In this
paper, we reported a 26-year-oldmale patient presenting to emergency
department with acute coronary syndrome and acute renal failure, who
had used various forms of cannabis for a long time and had a number
cardiovascular risk factors. The mechanism of action of cannabis was
also discussed herein.Case report
A 26-year-old male with no known chronic disease presented to the
emergency department with exertional dyspnea and chest pain. He
stated that his complaints had been recurring for 4–5 months but they
had recently increased in severity and frequency. He had been smoking
for 15 years and using illicit drugs for 12 years. Questioning about hisastanesi, Koroner Yoğun Bakım
33425; fax: +90 212 4596198.
).
diovascular Academy.
y. Production and hosting by Elsevsynthetic cannabinoid) for the last 2 years. His blood pressure was
160/100 mmHg and his pulse rate was 88 bpm. On physical examina-
tion, his skin was cold and pale. Cardiovascular examination revealed
aminations were normal. An ECG taken in the emergency department
was also normal. Creatinine level was 9 mg/dL, urea was 173 mg/dL,
and troponin level was 0.5 ng/dL. Troponin elevation was attributed to
markedly abnormal renal function and the patient was taken into dial-
ysis via a right femoral catheter. Following dialysis, he again had chest
pain, and thus was consulted with the cardiology department. On ECG,
there was a 0.5 mm St segment depression on leads DII, DIII and aVF
(Fig. 1). Troponin level was found to be 0.7 ng/dL. Therefore, he was
considered to sustain a high-risk unstable angina pectoris and admitted
to coronary care unit. Mid and apical septal segments were hypokinetic
on echocardiography. His left ventricular diameters increased and ejec-
tion fraction was around 50%. He also had mild mitral insufﬁciency.
Clopidogrel 600 mg was loaded along with acetylsalicylic acid 300 mg,
metoprolol 25 mg, enoxaparin 0.4 mg, atorvastatin 80 mg, and intrave-
nous nitrate infusion. A coronary angiogram was performed, which
showed a total occlusion in the right coronary artery (RCA) and a 50%
stenosis with a haziness appearance in left anterior descending artery
(LAD) (Fig. 2). Circumﬂex artery was normal. After balloon angioplasty
80% diffuse lesion appeared (Fig. 3). A stent was implanted to the RCA
with complete vessel opening. LAD lesion was decided to be medically
managed. Detailed laboratory tests were done during his intensive
care stay. His fasting blood glucose was 76 mg/dl, and the lipid param-
eters were as follows: total cholesterol 282 mg/dL, LDL-C219 mg/dL,
HDL-C 41 mg/dL, and triglyceride 107 mg/dL. Hemoglobin level was
7.9 and anemia was consistent with iron deﬁciency anemia. The patient
underwent a regular dialysis program and was administered 1 unit of
erythrocyte suspension. His medical therapy was arranged and he was
transferred with a plan to visit the nephrology department for continu-
ation of the dialysis program. A renal biopsy was scheduled but post-
poned due to fear of bleeding from dual antiplatelet therapy given
after percutaneous coronary intervention. At the control examination
2 months after the ﬁrst admission, he was still on the dialysis program.ier B.V. All rights reserved. This is an open access article under the CC BY-NC-ND license
Fig. 1. Figure showing 1 mm downslopping ST segment depression on leads DII, DIII and aVF.
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and smoking. He was on clopidogrel, acetylsalicylic acid, metoprolol,
amlodipin, and statin medication.
Discussion
Cannabis is produced from leaves of the plant C. sativa and is known
to be the most abused substance in rural and urban centers both in
Europe and in our country. It has various preparations worldwide, in-
cluding marijuana, hash, ganja, kubar, and bonzai. Its main effects are
through cannabinoid receptors in the heart, brain, spleen, blood vessels,
and immune system.3 Δ9- tetrahydrocannabinol (THC) is the molecule
that is responsible for pharmacological actions of cannabis. THC acutely
exerts a vasoconstrictor effect and, additionally, cardiac ischemia as a
result of an increase in cardiac workload, and postural hypotension.Fig. 2. 50% stenosis in left anterior descending artery with a hazziness appearance.Similarly, increased blood carboxyhemoglobin levels are responsible
for inadequate myocardial blood supply. In addition, cellular stress
resulting from oxidant gasses activates thrombocytes and increases
the amount of oxidized LDL and factor VII activity. Thus, it exerts chronic
adverse cardiovascular effects by inducing inﬂammatory responses.4 It
has also been shown to induce thrombus formationwithin the coronary
artery lumen.4 For all these reasons, cannabis has been implicated for
the development of coronary artery disease and triggering acute
coronary syndromes.4 As a result of these marked vascular actions,
cannabis-containing cigarettes may worsen angina.5 Literature dataFig. 3. Figure showing diffuse lesion appeared after baloon angioplasty in right coronary
artery.
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to marked sinus tachycardia and frequent premature ventricular depo-
larizations independent of whether atherosclerotic coronary artery dis-
ease is present or not.6 Cannabis use can lead to severe cardiovascular
events, not only in patients with traditional cardiovascular risk factors,
but also in young people without any risk factors.7 Our patient had
used marijuana for 6 years, kubar for 4 years, and bonzai for 2 years.
He presented to our clinic with acute coronary syndrome. We also
think that the acute coronary syndrome was a direct result of cannabis
consumption earlier that day in our case. It is known that cannabis in-
creases heart rate and blood pressure in low doses, while it lowers the
two in higher doses. Although our patient used bonzai on the day of ad-
mission, his hemodynamic proﬁle was within normal limits.
Literature data about the renal side effects of cannabis is quite limit-
ed. It has been reported that cannabis formulations, especially its intra-
venous forms, cause transient nonoliguric renal failure.8 Bhanushali
et al. reported 4 cases of acute renal failure as a result of synthetic can-
nabinoid use.8 Although we could not prove histopathologically, we
considered that acute renal failure was chronic. And we think that low
hemoglobin count was due to the chronic renal failure. The patient
was included in the hemodialysis program and he was on hemodialysis
at the latest visits.
There are various researches investigating the relationship between
cannabis use and metabolic parameters. Muniyapa et al9 and Berard
et al10 found lower HDL cholesterol levels in patients with cannabis
abusers compared to the controls. LDL cholesterol levels were similar
between cannabis abusers and controls in both of the investigations.
In our case, LDL cholesterol levels were higher probably due to the ge-
netic or dietary habits of the patient.
Conclusion
Cannabis use has been increasing worldwide. Thus, coronary heart
disease, acute coronary syndrome, and acute renal failure as a complica-
tion of cannabis use are likely to increase in the future. We believe that
our case suffered acute coronary syndrome and acute renal failure notonly because of conventional atherosclerotic risk factors such as hyper-
lipidemia and smoking, but also possibly because he had used cannabis
for an extended period before admission. Use of cannabis or other illicit
drugs should always be questioned in young cases presenting with
acute coronary syndrome and/or acute renal failure.Funding
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